Skip to content

White paper: Matching Antibody Discovery and Engineering Strategies to Program Goals

Case studies spanning in vivo, in vitro display, immune library, and lead optimization campaigns show how to match antibody discovery strategies to program goals.


Executive Summary:

Antibody programs can enter development through different antibody discovery strategies, each of which samples sequence and functional space in a distinct way. In vivo immunization leverages an adaptive immune response and somatic diversification, whereas in vitro display enables controlled selection from pre-existing antibody libraries. Immune library display sits between the two: antibody repertoires recovered from an immunized source are screened under the same controlled selection conditions that in vitro display offers. Once a lead has been identified, library-based engineering can be used to further optimize properties such as affinity, potency, specificity, or developability. This white paper examines representative examples from across this discovery-to-optimization continuum: an in vivo antibody discovery campaign using a fully human transgenic mouse platform, an in vitro display campaign designed to enrich conformation-selective binders, an immune library campaign pairing alpaca-derived and naive VHH libraries, and a library-based lead optimization campaign. The datasets were generated in separate programs and are not intended as a head-to-head comparison. Rather, they illustrate how different discovery and engineering strategies can be matched to different biological questions and program objectives.

The appropriate antibody discovery strategy depends on the biological question being addressed. Target class, antigen format, desired epitope or mechanism, tolerance to sequence constraints, requirements for species cross-reactivity, and the availability of functional screening assays can all influence platform selection. In vivo and in vitro discovery methods apply different forms of selection pressure and therefore sample antibody space differently. Neither approach eliminates the need for downstream characterization.

Likewise, not every desired property can be optimized during initial discovery. Once a promising molecule or family has been identified, targeted engineering can be used to refine attributes that remain outside the desired target profile. The sections below illustrate these complementary stages of antibody discovery and engineering.

2.1 Representative Platform: Atlas Full Human Diversity Mouse

In vivo antibody discovery uses the adaptive immune system to generate and select antibody repertoires following antigen exposure. The specific repertoire obtained depends on the host, genetic background, antigen design, immunization strategy, immune response, and recovery method. The case study presented here used the Atlas Full Human Diversity (FHD) transgenic mouse as one representative in vivo discovery system.

The Atlas FHD mouse is designed to maximize recovery of diverse, fully human antibody candidates while preserving the advantages of in vivo affinity maturation and immune selection. It captures full human diversity across both the heavy chain (HC) and kappa light chain (κ-LC) loci through more productive B-cell rearrangements. Variable region sequences used in the Atlas™ system encompass more than 99% of known and expressed human sequences, while avoiding

Request the White Paper- ADO

This field is for validation purposes and should be left unchanged.
Name(Required)